Abstract: A transdermal delivery system for the administering of progesterone and an estradiol ester alone or in combination utilizing a polymer matrix having the drug(s) along with a permeation enhancer dispersed throughout.

Abstract: A medical bandage is disclosed comprising a reservoir containing a gelled fluid, rheological agent and a drug. A method of using the bandage for producing a beneficial effect is disclosed also.

Abstract: A method is disclosed for treating an ischemic condition. The method comprises coadministering topically and internally a vasodilator to a patient having the condition for treating said condition.

Abstract: A medical device and method for the pulsatile administration of a drug through intact skin at a first steady state flux during a first delivery period and a second steady state flux during a second delivery period, said first flux being substantially higher than said second flux; said first and second delivery periods comprising a substantial portion of a predetermined administration period. The device comprises a reservoir of said drug containing an amount of drug sufficient to administer drug at said first and second steady state fluxes during administration period; a reservoir of a skin permeation enhancer for said drug; said reservoir containing an amount of said permeation enhancer sufficient to permit administration of said drug at said first flux only through said first delivery period; and means for maintaining said device on the skin in drug and permeation enhancer transferring relationship thereto a preferred embodiment delivering nitroglycerin and employing ethanol as a permeation enhancer.

Abstract: A high flux transdermal nitroglycerin therapeutic system is disclosed which is capable of delivering nitroglycerin through intact human skin at rates of 40 .mu.g/cm.sup.2 hr and preferably in the range of 50-150 .mu.g/cm.sup.2 hr. Ethanol delivered at a rate of from 250-500 .mu.g/cm.sup.2 hr is employed as a permeation enhancer for the nitroglycerin and a rate controlling membrane formed from ethylene vinyl acetate having a vinyl acetate content greater than 11% and preferably between 12-18% provides the appropriate rate control for both the drug and the permeation enhancer. This system is suitable for use in treatment of angina pectoris and congestive heart failure.

Abstract: A medical bandage is disclosed comprising a reservoir containing a gelled fluid, rheological agent and a drug. A method of using the bandage for producing a beneficial effect is disclosed also.

Abstract: A method is disclosed for treating an ischemic condition. The method comprises coadministering topically and internally a vasodilator to a patient having the condition for treating said condition.

Abstract: A medical device for the transdermal delivery of highly ionized, fat insoluble drugs comprises an aqueous drug reservoir having a physiological pH, said reservoir preferably being a gel maintained in an impermeable receptacle by a highly permeable support member disposed between the gel and a permeable contact adhesive. A permeation enhancer reservoir delivers a permeation enhancer to the skin through the aqueous reservoir and through a permeation enhancer release rate controlling membrane which is permeable to the permeation enhancer and impermeable to the drug and water. In a preferred embodiment the permeation enhancer release rate controlling membrane forms at least a portion of said receptacle.

Abstract: A high flux transdermal nitroglycerin therapeutic system is disclosed which is capable of delivering nitroglycerin through intact human skin at rates of 40 .mu.g/cm.sup.2 hr and preferably in the range of 50-150 .mu.g/cm.sup.2 hr. Ethanol delivered at a rate of from 250-500 .mu.g/cm.sup.2 hr is employed as a permeation enhancer for the nitroglycerin and a rate controlling membrane formed from ethylene vinyl acetate having a vinyl acetate content greater than 11% and preferably between 12-18% provides the appropriate rate control for both the drug and the permeation enhancer. This system is suitable for use in treatment of angina pectoris and congestive heart failure.

Abstract: Transdermal delivery systems for delivery of fentanyl and its analgetically effective derivatives for extended periods of time are disclosed which deliver the base form of the drug at a rate of from 0.5 to 10 .mu.g/cm.sup.2 /hr for a substantial portion of their useful life. The systems can be from 5-100 cm.sup.2 in releasing surface and preferably employ an in-line amine resistant adhesive. Preferred rate controlled systems utilize an aqueous ethanolic gel to minimize drug content.

Abstract: Mineral oil (MO) polyisobutylene (PIB), colloidal silicon dioxide (CSD) mixtures suitable for use as drug containing matrices in transdermal delivery systems are disclosed. Preferred systems for dispensing moderately mineral oil soluble drugs contain at least about 6% CSD, have a MO/PIB of at least 1.0 and a viscosity of at least 1.5.times.10.sup.7 poises. Preferred systems for dispensing clonidine have a clonidine permeability of at least 1.0.times.10.sup.-4 .mu.g/cm sec and a MO/PIB of at least 1.2.

Abstract: A patient-care apparatus is disclosed for providing a biocide for controlling the presence of unwanted pathogens in a liquid. The patient-care apparatus comprises a container having means for maintaining a biocide dispensing device in a position in the container such that it dispenses an amount of biocide relative to the amount of liquid present in the container.

Abstract: A method is disclosed for treating an ischemic condition. The method comprises coadministering topically and internally a vasodilator to a patient having the condition for treating said condition.

Abstract: An ocular insert and an ocular composition are disclosed. The insert and the composition comprises a steroid in two different forms.

Abstract: An ocular insert and an ocular composition are disclosed. The insert and the composition comprises a steroid in two different forms.

Abstract: An ocular insert and an ocular composition are disclosed. The insert and the composition comprises a steroid in two different forms.

Abstract: An ocular therapeutic system is disclosed for dispensing a medicament to an ocular environment. The system comprises a beta-blocking drug in a polymer with the drug surrounded by the polymer. A method is disclosed for the management of ocular hypertension using the system. Also disclosed, is a composition comprising the drug and the polymer.

Abstract: A drug delivery system is disclosed useful for controlled ocular therapy. The system is manufactured as an ocular insert, and it comprises a beta-adrenergic blocking osmotic solute and a parasympathomimetic osmotic solute dispersed in a polymer with the solutes surrounded by the polymer. The system, when placed in the eye, delivers both drugs at a controlled rate over time. A method also is disclosed for the management of intraocular pressure using the ocular system.

Abstract: An ocular system is disclosed for dispensing a medication formulation to the eye. The system comprises a formulation consisting of a pilocarpine osmotic solute and an epinephrine osmotic solute dispersed in a polymer such that the formulation is surrounded substantially individually by the polymer. The system, when placed in the eye, dispenses the formulation at a controlled rate over time. A method also is disclosed for the management of intraocular pressure using the ocular system.